5.6 Human-Subjects Research Standards & Patient Access to Information
Key Takeaways
- The Common Rule and IRB review govern human-subjects research; clinical care testing follows clinical consent/quality pathways and is not automatically “research.”
- Distinguish research participation (protocol, IRB, study consent) from clinical genetic testing ordered for diagnosis/management—even when a lab also has a research repository.
- Patients generally have rights to access their medical records and results under HIPAA access provisions, with limited exceptions and institutional processes.
- The right not to know—declining results or certain secondary findings—is a recognized autonomy interest that counselors must respect and document within clinical/policy limits.
- Board vignettes often test whether the next step is IRB/research consent, clinical consent, facilitating record access, or honoring a preference not to receive information.
Research standards and access rights in Domain 5C
The final Domain 5C cluster ties human-subjects research standards to patient access to information. Genetic counselors work at the seam of clinical testing, biobanking, return of results, and client autonomy—including the choice not to learn certain information. Boards test whether you can tell research from clinical care, when an Institutional Review Board (IRB) matters, and how to honor access and “not knowing” preferences within policy.
The Common Rule and IRB oversight
The Federal Policy for the Protection of Human Subjects (the Common Rule, including the 2018 revisions as implemented) sets baseline requirements for much federally funded or otherwise covered human-subjects research in the United States. Institutions apply IRB review to determine whether an activity is research involving human subjects, whether it is exempt, and what consent and safeguards are required.
| Concept | Meaning for genetics practice | Exam cue |
|---|---|---|
| Human-subjects research | Research involving living individuals via interaction/intervention or identifiable private information, per regulatory definitions | Is this a study or clinical care? |
| IRB | Committee reviewing risks, benefits, consent, privacy, and subject selection | “Do we need IRB approval before recruiting?” |
| Informed consent (research) | Study-specific consent addressing purpose, procedures, risks, benefits, alternatives, confidentiality, voluntariness, whom to contact | Handing a clinical test consent and calling it research consent |
| Exempt / expedited / full review | Pathways based on risk and design (high-level awareness) | Not all chart reviews are identical |
| Return of research results | Protocol-dependent; may differ from clinical reporting standards | “Will I get my research sequencing back?” |
Why counselors must care
- Recruiting clinic patients into studies requires clear separation of clinical relationship and research invitation—no coercion (“you only get counseling if you enroll”).
- Residual samples sent to a research repository need appropriate consent/authorization pathways.
- Research results may be preliminary, lack CLIA clinical validation, or be non-returnable under the protocol—counsel accordingly.
- Secondary findings policies in research may differ from clinical ACMG-style frameworks.
Research testing vs clinical testing
This distinction is a Domain 5C favorite.
| Feature | Clinical genetic testing | Research genetic testing / study sequencing |
|---|---|---|
| Purpose | Diagnosis, management, reproductive decisions for this patient | Answer a scientific question; generalizable knowledge |
| Oversight | Clinical consent, lab accreditation (e.g., CLIA), institutional clinical policies | IRB/protocol, research consent, sponsor rules |
| Result use | Placed in medical record for care (typical) | May be summary only, delayed, partial, or not returned |
| Billing | Insurance/self-pay clinical pathways | Often study-funded; not a substitute for denied clinical care without clarity |
| Reanalysis duty | Clinical policies/evolving standards | Protocol-defined |
Hybrid traps: A clinical lab may ask permission to store de-identified data for research, or a study may offer clinical confirmatory testing. Best counseling names each pathway, what will be returned, and what goes in the medical record.
Scenario cue: If the vignette says “protocol,” “IRB,” “study arm,” or “not returned to participants,” think research. If it says “ordered for diagnosis,” “CLIA lab,” “medical record,” think clinical—even if the patient hopes researchers will “also look.”
Patient access to results and records
Under the HIPAA Privacy Rule, individuals generally have a right of access to inspect and obtain copies of PHI in a designated record set, including many clinical genetic test reports and counseling notes, subject to limited exceptions (for example, certain psychotherapy notes or circumstances involving serious harm as defined in regulation/policy). Practical counseling points:
- Facilitate lawful access — tell patients how to request records through health-information management/portals; do not invent barriers.
- Timeliness — institutions must follow regulatory and policy timelines; counselors help navigate, not obstruct.
- Interpretation vs dump — patients can access reports; counselors still offer interpretive sessions so raw data are not mistaken for clinical advice.
- Third-party apps / downloads — patients may export data; discuss privacy risks without unlawfully blocking access.
- Minors and proxies — access rules involve parental rights, adolescent confidentiality policies, and personal representatives—follow institutional/legal frameworks.
| Access request | Appropriate response | Inappropriate response |
|---|---|---|
| Patient wants copy of variant report | Explain request process; offer counseling visit | “Genetics results are never releasable to patients” |
| Patient wants research-only sequencing file | Check protocol—research data access may differ from clinical designated record set | Promise clinical-grade interpretation of non-CLIA research data |
| Relative wants patient’s record | Authorization/personal representative rules (see 5.5) | Release because of shared DNA |
| Patient disputes a note | Explain amendment request process | Silently rewrite history without process |
The right not to know
Autonomy includes declining information. In genetics this appears as:
- Declining predictive testing entirely.
- Declining secondary findings analysis when optional.
- Asking not to be told a particular category of results (within what the lab/order can operationalize).
- Preferring staged disclosure (e.g., learn cancer risk results first, defer neurodegenerative risk if separable).
| Principle | Counseling application | Limit |
|---|---|---|
| Right not to know | Respect refusal of predictive information after adequate explanation of implications | Cannot always un-order a test already resulted in the chart—plan preferences before analysis when possible |
| Informed refusal | Document what was declined and that residual risks/family implications were discussed | Refusal does not erase duties to document and offer future contact |
| Family implications | Still discuss that relatives may benefit if the patient later shares or if other pathways exist | Do not coerce testing “for the family” |
| Clinically urgent results | Some findings may be hard to silo once ordered (panel design) | Choose tests that match informational preferences when feasible |
Exam distractors: forcing unwanted predictive results “because knowledge is always better,” or conversely refusing to discuss that declining testing has family and medical consequences.
Integrating research, access, and not-knowing
Scenario A — clinic vs study: Parents want exome for a child’s epilepsy. A researcher offers “free research exome” with no clinical report. Best counseling: research exome may not replace CLIA clinical testing for care; if they need results for management, pursue clinical testing (with insurance/resource navigation as in Domain 5A–B). Study enrollment is voluntary and separate.
Scenario B — access: Adult patient requests download of their clinical gene panel PDF from the portal. Best action: support access through proper channels and offer an interpretive appointment—not withhold the report to force an in-person visit if policy grants electronic access.
Scenario C — not to know: Asymptomatic client wants testing only for a known familial cardiovascular variant and declines opportunistic secondary finding categories that the lab can exclude. Best action: order/consent consistent with that preference when technically available; document informed refusal of additional analysis.
Scenario D — recontact research: A past study participant is recontacted because a variant is now classified pathogenic. Best awareness: follow protocol/consent terms and institutional process for recontact; do not assume identical rules to clinical reanalysis programs.
Common traps
- Treating research sequencing as equivalent to clinical diagnosis without confirmatory pathways.
- Coercing study enrollment as a condition of clinical care.
- Blocking patient access to clinical records contrary to HIPAA access rights.
- Ignoring the right not to know or, opposite error, never explaining consequences of not knowing for medical/family decisions.
- Assuming research data automatically enter the medical record—or that clinical data may be dropped into a public dataset without consent/IRB pathways.
Quick exam checklist
- Is the activity clinical care or human-subjects research (IRB/protocol)?
- Will results be returned, CLIA-confirmed, and charted?
- Is the patient seeking access to their own records vs a third party seeking disclosure?
- Did we honor not knowing preferences within what the test design allows—and document informed refusal?
- Are consent documents matched to the actual pathway (clinical vs research)?
Parents are offered a no-cost research exome for their child with a clear clinical indication for diagnostic testing. The protocol states research results are not returned for clinical use. What is the best counseling distinction?
An adult patient requests a copy of their clinical genetic test report from the medical record. Assuming no applicable regulatory exception, what is the most appropriate counselor stance?
A client wants testing for a known familial pathogenic variant but clearly declines optional secondary-findings analysis that the laboratory can exclude. Which action best respects the right not to know?
A genetic counselor wants to invite consecutive clinic patients into a biobank study during the same visit as diagnostic consent. Which practice best reflects human-subjects research standards?